Ningbo Sanxing Medical Electric Co (601567) Q2 2024 earnings summary

Executive summary

• Revenue reached ¥6.997 billion for H1 2024, up 26.11% year-over-year; net profit attributable to shareholders was ¥1.15 billion, up 32.23% year-over-year.

• Gross margin improved to 34.61%, an increase of 3.49 percentage points year-over-year.

• Both smart power distribution and medical services segments delivered strong growth, with significant expansion in overseas and domestic markets.

• No interim dividend distribution was proposed for the reporting period.

Financial highlights

• Operating income: ¥6.997 billion, up 26.11% year-over-year.

• Net profit attributable to shareholders: ¥1.15 billion, up 32.23% year-over-year.

• Operating cash flow: ¥260 million, up 45.96% year-over-year.

• Basic and diluted EPS: ¥0.81, up 30.65% year-over-year.

• Net assets attributable to shareholders: ¥11.108 billion, up 0.93% from year-end 2023.

Outlook and guidance

• Management expects continued strong demand in both smart grid and medical rehabilitation sectors, driven by domestic and international infrastructure investment and aging demographics.

• The company will focus on expanding overseas market share, deepening local operations, and accelerating the rollout of new energy and digital solutions.